Crisugabalin
Neuropathic Pain
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySmall moleculePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
52 Active assets in the Neuropathic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin Ziauddin University | Phase 4 | A |
Bxcl501 Universidad Juárez Autónoma de Tabasco | Phase 4 | BBB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Ataturk University | Phase 4 | BBB |
Capsaicin NeurogesX | Phase 3 | BBB |
LIDOCAINE Ataturk University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Crisugabalin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →